Risk Drivers
See which FDA risks are building around each site.
483Radar ties BlindSpot, observation risk, and inspection-pressure signals back to dated FDA evidence, so leaders can see what is changing before it becomes inspection exposure.
FDA Inspection Readiness Intelligence for Quality and Regulatory Teams
FDA Inspection Risk Software for Pharma and Device Quality Teams
483Radar turns FDA Form 483 citation trends, inspection pressure, and warning letter signals into a scored facility view, a dated executive brief, and one clear first action for pharma and device quality teams.
Discovery calls are hosted by LeanStorming, the team behind 483Radar.
ScopeSingle-facility beta pilot
DeliveryGuided MVP workflow + executive brief
Evidence57k inspection / 44k citation records
FreshnessApr 10, 2026
Product Journey
A clearer way to discover what 483Radar does.
Scroll through the product story: the dashboard, the risk drivers, the executive brief, and the action path.
Executive Brief
Turn FDA signal into an executive brief leadership can act on.
483Radar turns FDA inspection data, Form 483 patterns, and citation signals into clear briefs for QA, regulatory, and operations leaders.
Action Path
Give Quality, Ops, and Finance the same next move.
The product narrows external FDA pressure into one practical decision path before the next inspection cycle tightens.
What To Do Next
Run the first decision in 15 minutes.
Stop treating every emerging CFR signal like the same problem. In 15 minutes, narrow to the CFR domain, timing window, first review path, and sponsor-level ask that matter first.
Map the external CFR signal
Minute 1-5Identify the CFR domains building fastest around facilities like yours so review starts with external evidence, not internal noise.
Put timing on the risk
Minute 5-8Assess whether that signal is likely to convert into inspection activity or elevated observation risk in the next 6 to 12 months.
Choose the first gap that matters
Minute 8-12Focus the review on the control gap with the highest probable exposure instead of spreading effort across every theoretical concern.
Arm leadership to act
Minute 12-15Turn the signal into a clear leadership brief with the exposure, likely cost, and immediate action worth sponsoring.
Internal Selling Power
Help every function agree on what to fix first.
When Quality, Operations, Finance, and leadership all see FDA risk differently, scarce resources get spread thin. 483Radar translates inspection signals into the language each function needs, so teams can align on the risks most likely to affect compliance, throughput, cost, and escalation.
VP Quality
- See which compliance risk deserves the first review.
- Identify the CFR themes most likely to convert into inspection pressure.
- Challenge weak internal assumptions with dated FDA evidence.
- Focus limited review capacity on the control gap most likely to matter.
VP Operations
- See which gaps could disrupt execution first.
- Identify unresolved issues most likely to affect throughput, service, or production stability.
- Time corrective action before inspection pressure turns into operational disruption.
- Use planned windows instead of pulling teams into emergency response.
CFO
- See where delay could become avoidable cost.
- Understand the financial exposure before remediation costs escalate.
- Compare which risks are most likely to drive disruption, rework, or urgent spend.
- Fund targeted action early instead of paying for a broader response later.
Executive Leadership
- See where the business needs one focused decision.
- Understand whether the issue is contained or likely to widen.
- Align Quality, Operations, and Finance around the risk that deserves action first.
- Make one coordinated decision early instead of managing escalation later.
Proof
Under the hood: deterministic FDA risk modeling.
483Radar is not a keyword search layer or a generic AI summary. It calculates FDA inspection risk using structured citation history, site exposure, cohort behavior, time-based inspection pressure, and reliability thresholds, then shows only the signals strong enough to support review.
01
BlindSpot runs nine deterministic signal families — not keyword matching. Each candidate scores across three weighted dimensions: external strength, site exposure gap, and consequence weight, multiplied by an evidence-quality confidence factor. Priority score below 0.9: suppressed. Peer cohort under six facilities: raw count signals disabled.
02
Observation Risk uses empirical Bayes-style shrinkage across a five-level cohort hierarchy — district × product × process down to a neutral baseline. Inspections are labeled positive only when linked citations, posted 483s, or VAI/OAI classification are present. Thin cohorts shrink toward the parent, not toward zero. Reliability resolves to one of four levels — HIGH, MODERATE, LOW, INSUFFICIENT — and governs how far the score can move from the contextual baseline.
03
Inspection Pressure runs a Cox proportional hazards model: 16 features, C-index 0.6815, trained on 262,129 survival episodes across 130,182 facilities. IPS-3, IPS-6, and IPS-12 are separate forecasts — not the same number at different zoom levels.
04
Reliability is computed per signal before the brief is assembled. A claim that fails the evidence threshold is suppressed — not footnoted, not asterisked, not softened. Gone.
Pricing
Give leadership a sharper way to separate signal from quality noise.
Single Facility
Review one facility now. One site. One operator. One beta brief.
$1,795/mo
Beta launch price$1,195/moGuided beta pricing. Platform access follows.Beta price is locked for founding teams after launch.
ScopeSingle-facility beta
RefreshWeekly FDA sync
OutputExecutive brief PDF
BlindSpot BriefWhich CFR areas are gaining inspection attention?
Observation OutlookWhat happens if FDA inspects?
Inspection OutlookHow likely is an FDA inspection?
- Single-facility beta pilot scope
- 1 named operator seat
- Weekly FDA dataset refresh
- BlindSpot, Observation, and Inspection scoring
- Shareable executive brief PDF
- MarketRadar company FDA search
- Priority transition into the full platform rollout
Scheduling is handled through LeanStorming.com.
Final CTA
See where your FDA exposure is building before your next inspection.
If external pressure is already forming and you are not tracking it, you are deciding late. Start with one facility in the guided beta pilot, surface the first risk, and set the first action now.
Hosted by LeanStorming with Dave Cortes.